Molecular mechanisms involved in SCLC are not well understood, but dysregulation of tumor suppressor genes (e.g., TP53, RB1) and activation of oncogenic signaling pathways (e.g., PI3K/AKT, MAPK) have been shown to be involved. The gene discussed is TP53; the disease is small cell lung carcinoma.